BIOS Health has announced a partnership with the city of Bakersfield in Kern County, California, and the Kern Venture Group, to set up a precision medicine centre in the US state.
The facility will serve as a hub for neural clinical trials and research and development (R&D) utilising BIOS’s adaptive dosing technology.
It will become BIOS Health’s West Coast hub, aiming to be the premier location for neural clinical trials and R&D.
The move is part of the company’s plan to accelerate its commercialisation strategy in the US market.
The centre will also leverage BIOS Health’s real-time insights into the nervous system.
BIOS Health will work with regional partners to set up the new research and clinical trials centre for neural digital therapies.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Its adaptive dosing technology, which incorporates neural biomarkers and artificial intelligence (AI), allows for the observation and adjustment of drug effects on the nervous system in real time.
The establishment of the Bakersfield centre will boost operations, quickly reach more people and establish a collaborative ecosystem of clinicians, pharmaceutical and medical device enterprises and clinical trial partners.
The centre’s focus on real-time neural research for trials is set to attract an ecosystem interested in identifying new medicines and improving clinical trial success rates.
This is BIOS Health’s second international hub, following the establishment of an AI and neuroscience research site in Montreal, Canada, in 2018.
In 2023, BIOS Health received a growth round of funding from key partners, including the Kern Venture Group.
BIOS Health CEO Emil Hewage stated: “We are excited to be creating the infrastructure, alongside our regional, clinical and commercial partners, to deliver a new future for precision medicine development.
“Our adaptive dosing technology can offer a new type of clinical trial in which we observe and interpret the neural response of patients in real time.
“Soon, treatment decisions that used to take months, or even prove to be impossible, will be available to clinicians and patients at their fingertips.”
